(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 September 2021 (10.09.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/178807 A1

(51) International Patent Classification:
A61K 31/513 (2006.01) *A61P 35/00* (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/US2021/021101

(22) International Filing Date:
05 March 2021 (05.03.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/986,541 06 March 2020 (06.03.2020) US

(71) Applicant: **CELGENE QUANTICEL RESEARCH, INC.** [US/VA]; 9393 Town Centre Drive, Suite 110, San Diego, California 92121 (US).

(72) Inventors: **FILVAROFF, Ellen**; 86 Morris Avenue, Summit, New Jersey 07901 (US). **ARONCHIK, Ida**; 86 Morris Avenue, Summit, New Jersey 07901 (US). **CHOW, Tracy**; 86 Morris Avenue, Summit, New Jersey 07901 (US). **OLSON, Eric**; 86 Morris Avenue, Summit, New Jersey 07901 (US). **FOX, Brian**; 86 Morris Avenue, Summit, New Jersey 07901 (US). **WANG, Maria**; 86 Morris Avenue, Summit, New Jersey 07901 (US).

(74) Agent: **SIMKIN, Michele M.** et al.; Foley & Lardner LLP, 3000 K Street NW, Suite 600, Washington, District of Columbia 20007-5109 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*

WO 2021/178807 A1

(54) Title: COMBINATION OF AN LSD-1 INHIBITOR AND NIVOLUMAB FOR USE IN TREATING SCLC OR SQNSCLC

(57) Abstract: The present application relates generally to a lysine specific demethylase-1 (LSD-1) inhibitor, or a pharmaceutically acceptable salt thereof, and nivolumab, for use in methods for treating small cell lung cancer (SCLC) and/or squamous non-small cell lung cancer (sqNSCLC).